InforSense Ltd has announced that AstraZeneca has strengthened their strategic commitment to InforSense technology across their research and development organization through a new multi-year global licensing deal.
Scientists at AstraZeneca R&D sites will use InforSense’s workflow-based integrative analytics environment, InforSense® KDE, to derive research intelligence and enhance productivity in their core drug discovery programs.
InforSense technology has been used at AstraZeneca since 2001. Following pilot installations, the global licensing agreement expands access to InforSense KDE across their R&D organization for integrative biology, chemistry and text mining applications.
The agreement also includes professional services by InforSense to enable AstraZeneca to leverage their existing discovery software investments within InforSense KDE workflows.
"InforSense is delighted to expand our ongoing collaboration with AstraZeneca," commented Joseph F. Donahue, Chief Business Officer of InforSense.
"One of the major competitive discriminators between Pharma R&D pipelines will be the speed and effectiveness by which they integrate both external and internal data, as well as software tools, within and across domains."
"InforSense technology will enable AstraZeneca to provide such integration across their entire organization to leverage their knowledge of biology and chemistry research in new ways."
"We have recognized the potential value of InforSense integrative analytics technology at AstraZeneca for effective research decision-making over recent years," said Martyn Wilkins, Director of Discovery Informatics Portfolio at AstraZeneca.
"By expanding our commitment to InforSense KDE, we will empower more scientists across our organization to effectively use information-driven analytics to inform and accelerate their research."